DVAX▼
ザックス、BMW、DXCテクノロジー、ダイナバックスを「強い売り」リストに追加
ザックス・インベストメント・リサーチは本日、3銘柄をザックスランク5（強い売り）リストに追加しました。バイエリッシェ・モトーレン・ヴェルケ（BMW）は、今期の利益コンセンサス予想が過去60日間で8.2%下方修正されました。DXCテクノロジーは同期間に18.2%、ダイナバックス・テクノロジーズは50%の下方修正となりました。
← Back
![]()
Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Country
Sector
Themes
Also in